ARVN - Arvinas GAAP EPS of -$1.20 misses by $0.28 revenue of $24.2M misses by $1.31M

Arvinas press release (NASDAQ:ARVN): Q1 GAAP EPS of -$1.20 misses by $0.28. Revenue of $24.2M (+336.8% Y/Y) misses by $1.31M. “It has been a very productive first quarter for Arvinas, as we prepare to initiate three planned pivotal clinical studies in the second half of 2022 for our two lead programs – ARV-471 in metastatic breast cancer and bavdegalutamide in molecularly defined metastatic castration-resistant prostate cancer,” said John Houston, Ph.D., chief executive officer and president at Arvinas. “We have a unique opportunity to bring these two programs into late-stage development at the same time, demonstrating the potential of our PROTAC® platform to selectively and efficiently degrade and remove disease-causing proteins.”

For further details see:

Arvinas GAAP EPS of -$1.20 misses by $0.28, revenue of $24.2M misses by $1.31M